10.1038/s41571-020-00462-0 Nat Rev Clin Oncol
Generally well-tolerated BPC-157 has a favorable side-effect profile
Crystallization of Pt GSTF8 in presence of ()-catechin and GSH Purified Pt GSTF8 in 30 mM Tris, pH 8, 200 mM NaCl, 1 mM EDTA was concentrated to 12.4 mg ml 1 using an Amicon Ultra-4 device (10 kDa cut-off) (Merck Millipore) and supplemented with 1 mM GSH and 25 mM ()-catechin immediately before crystallization
To further compare GSH synthetic capacities of different pathways, GSH1 gene of engineered strain W303-1b/F was deleted to eliminate synthesis of GSH by endogenous enzymes
These secondary benefits may influence which compound a researcher selects
FDA Disclaimer: These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease